Page 2 - Liver Unit News Today

Durvalumab plus a single priming dose of tremelimumab led to continued clinically meaningful overall survival benefit at 4 years compared with sorafenib in patients with previously untreated, unresectable hepatocellular carcinoma not eligible for localized therapy.

The figures are alarming: An estimated 18 million Filipinos are either suffering from liver disease or are at risk of getting it.

A HEARTBROKEN mum who took her own life as the anniversary of her sons death approached was the subject of several missed opportunities by…

Hepatocellular carcinoma and lung cancer patients are set to benefit from the recent approval of Imfinzi plus Imjudo combinations in the EU.

A Kilkeny native is part of an aspiring trio who are getting set to run all the way from Monaghan to Mayo (210km) as part of a special charity fundraiser. Bob G...

Investegate announcements from AstraZeneca PLC, Imfinzi + Imjudo recommended for approvals in EU

Patients with cholestatic liver disease such as primary biliary cholangitis (PBC) can experience significant impairment of bile flow and may develop neurological symptoms including fatigue and cognitive decline.

GHENT, Belgium, June 07, 2022 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication of

Investegate announcements from MRM Health NV, MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis

MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis GlobeNewswire June 07, 2022 GHENT, Belgium, June 07, 2022 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication of preclinical research relating to its...